Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 20-Nov-24 7:55 AM View:  | McCracken Joseph S Director | Adventrx Pharmaceuticals Inc. (SVRA) | 19-Nov-24 | Purchase | 20,000 | $2.95 | $59,072.00 | 10% 190.84K to 210.84K | |
| 18-Nov-24 12:33 PM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 18-Nov-24 | Purchase | 100,000 | $2.88 | $287,600.00 | 4% 2.22M to 2.32M | |
| 27-Sep-24 4:35 PM View: | Parker Braden C. Chief Commercial Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 25-Sep-24 | Grant | 85,000 | -- | -- | 100% 0 to 85.0K | |
| 22-Jul-24 4:16 PM View: | Erickson Anne Chief Business Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 21-Jul-24 | Payment of Exercise | 381 | $4.47 | $1,703.07 | (< 1%) 353.7K to 353.32K | |
| 23-Apr-24 4:06 PM View: | Erickson Anne Chief Business Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 21-Apr-24 | Payment of Exercise | 381 | $4.81 | $1,832.61 | (< 1%) 354.08K to 353.7K | |
| 29-Dec-23 4:34 PM View: | Lowrance David L Chief Financial Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 28-Dec-23 | Private Sale | 10,000 | $4.71 | $47,131.00 | (3%) 352.36K to 342.36K | |
| 29-Dec-23 4:33 PM View: | Elam Nevan C Director | Adventrx Pharmaceuticals Inc. (SVRA) | 28-Dec-23 | Private Option Sale | 53,758 | $4.71 | $253,367.00 | (46%) 116.34K to 62.59K | |
| 29-Dec-23 4:35 PM View: | Pauls Matthew CHIEF EXECUTIVE OFFICER Director | Adventrx Pharmaceuticals Inc. (SVRA) | 28-Dec-23 | Gift | 19,000 | -- | -- | (1%) 1.39M to 1.37M | |
| 29-Dec-23 4:33 PM View: | Elam Nevan C Director | Adventrx Pharmaceuticals Inc. (SVRA) | 28-Dec-23 | Sale | 40,085 | $4.71 | $188,925.00 | (64%) 62.59K to 22.5K | |
| 29-Dec-23 4:35 PM View: | Pauls Matthew CHIEF EXECUTIVE OFFICER Director | Adventrx Pharmaceuticals Inc. (SVRA) | 28-Dec-23 | Sale | 84,000 | $4.71 | $395,900.00 | (6%) 1.37M to 1.28M | |
| 29-Dec-23 4:33 PM View: | Elam Nevan C Director | Adventrx Pharmaceuticals Inc. (SVRA) | 28-Dec-23 | Option Exercise | 53,758 | $1.30 | $69,721.60 | 86% 62.59K to 116.34K | 1% |
| 15-Dec-23 5:55 PM View: | Lowrance David L Chief Financial Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 15-Dec-23 | Gift | 20,000 | -- | -- | (5%) 372.36K to 352.36K | |
| 15-Dec-23 5:46 PM View: | Pauls Matthew CHIEF EXECUTIVE OFFICER Director | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Payment of Exercise | 109,680 | $4.45 | $488,076.00 | (7%) 1.5M to 1.39M | |
| 15-Dec-23 5:55 PM View: | Lowrance David L Chief Financial Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Grant | 160,000 | -- | -- | 66% 242.79K to 402.79K | |
| 15-Dec-23 5:33 PM View: | Hawkins Richard J Director | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Grant | 22,500 | -- | -- | 177% 12.74K to 35.24K | |
| 15-Dec-23 5:32 PM View: | Elam Nevan C Director | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Grant | 22,500 | -- | -- | 56% 40.09K to 62.59K | |
| 15-Dec-23 5:51 PM View: | Lutz Robert Matthew Chief Operating Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Grant | 160,000 | -- | -- | 114% 140.0K to 300.0K | |
| 15-Dec-23 5:37 PM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Grant | 22,500 | -- | -- | 1% 2.2M to 2.22M | |
| 15-Dec-23 5:55 PM View: | Lowrance David L Chief Financial Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Payment of Exercise | 30,438 | $4.45 | $135,449.00 | (8%) 402.79K to 372.36K | |
| 15-Dec-23 5:35 PM View: | van Es-Johansson An Director | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Grant | 22,500 | -- | -- | 100% 0 to 22.5K | |
| 18-Dec-23 4:05 PM View: | Pratt Raymond Dennis Chief Medical Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Grant | 150,000 | -- | -- | 94% 160.0K to 310.0K | |
| 15-Dec-23 5:46 PM View: | Pauls Matthew CHIEF EXECUTIVE OFFICER Director | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Grant | 450,000 | -- | -- | 43% 1.05M to 1.5M | |
| 15-Dec-23 5:28 PM View: | McCracken Joseph S Director | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Grant | 22,500 | -- | -- | 13% 168.34K to 190.84K | |
| 15-Dec-23 6:10 PM View: | Sun Ricky Director | Adventrx Pharmaceuticals Inc. (SVRA) | 14-Dec-23 | Grant | 22,500 | -- | -- | 100% 0 to 22.5K | |
| 12-Dec-23 6:09 PM View: | Hawkins Richard J Director | Adventrx Pharmaceuticals Inc. (SVRA) | 11-Dec-23 | Option Exercise | 10,841 | $0.82 | $8,889.62 | 571% 1.9K to 12.74K | |
| 12-Dec-23 6:08 PM View: | Elam Nevan C Director | Adventrx Pharmaceuticals Inc. (SVRA) | 11-Dec-23 | Option Exercise | 10,841 | $0.82 | $8,889.62 | 37% 29.24K to 40.09K | |
| 19-Jul-23 7:04 PM View: | Growth Equity Opportunities... 10% Owner | Adventrx Pharmaceuticals Inc. (SVRA) | 17-Jul-23 | Purchase | 333,333 | $3.00 | $999,999.00 | 1% 24.14M to 24.47M | |
| 19-Jul-23 7:07 PM View: | Chang Carmen 10% Owner | Adventrx Pharmaceuticals Inc. (SVRA) | 17-Jul-23 | Purchase Duplicate | 333,333 | $3.00 | $999,999.00 | 1% 24.14M to 24.47M | |
| 19-Jul-23 7:10 PM View: | Mathers Edward T 10% Owner | Adventrx Pharmaceuticals Inc. (SVRA) | 17-Jul-23 | Purchase Duplicate | 333,333 | $3.00 | $999,999.00 | 1% 24.14M to 24.47M | |
| 19-Jul-23 7:13 PM View: | Yang Rick 10% Owner | Adventrx Pharmaceuticals Inc. (SVRA) | 17-Jul-23 | Purchase Duplicate | 333,333 | $3.00 | $999,999.00 | 1% 24.14M to 24.47M | |
| 19-Jul-23 7:05 PM View: | Baskett Forest 10% Owner | Adventrx Pharmaceuticals Inc. (SVRA) | 17-Jul-23 | Purchase Duplicate | 333,333 | $3.00 | $999,999.00 | 1% 24.14M to 24.47M | |
| 19-Jul-23 7:08 PM View: | Florence Anthony A. Jr. 10% Owner | Adventrx Pharmaceuticals Inc. (SVRA) | 17-Jul-23 | Purchase Duplicate | 333,333 | $3.00 | $999,999.00 | 1% 24.14M to 24.47M | |
| 19-Jul-23 7:11 PM View: | Sandell Scott D 10% Owner | Adventrx Pharmaceuticals Inc. (SVRA) | 17-Jul-23 | Purchase Duplicate | 333,333 | $3.00 | $999,999.00 | 1% 24.14M to 24.47M | |
| 19-Jul-23 7:06 PM View: | Behbahani Ali 10% Owner | Adventrx Pharmaceuticals Inc. (SVRA) | 17-Jul-23 | Purchase Duplicate | 333,333 | $3.00 | $999,999.00 | 1% 24.14M to 24.47M | |
| 19-Jul-23 7:09 PM View: | Makhzoumi Mohamad 10% Owner | Adventrx Pharmaceuticals Inc. (SVRA) | 17-Jul-23 | Purchase Duplicate | 333,333 | $3.00 | $999,999.00 | 1% 24.14M to 24.47M | |
| 19-Jul-23 7:12 PM View: | Walker Paul Edward 10% Owner | Adventrx Pharmaceuticals Inc. (SVRA) | 17-Jul-23 | Purchase Duplicate | 333,333 | $3.00 | $999,999.00 | 1% 24.14M to 24.47M | |
| 27-Jun-23 7:00 AM View: | Pratt Raymond Dennis Chief Medical Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 26-Jun-23 | Purchase | 6,500 | $2.93 | $19,045.00 | 4% 153.5K to 160.0K | |
| 26-May-23 11:31 AM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 26-May-23 | Purchase | 37,124 | $2.63 | $97,599.00 | 2% 2.16M to 2.2M | |
| 26-May-23 11:31 AM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 25-May-23 | Purchase | 12,876 | $2.57 | $33,129.90 | < 1% 2.15M to 2.16M | |
| 26-May-23 11:31 AM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 24-May-23 | Purchase | 50,000 | $2.56 | $127,800.00 | 2% 2.1M to 2.15M | |
| 28-Feb-23 4:31 PM View: | Lutz Robert Matthew Chief Operating Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 24-Feb-23 | Grant | 140,000 | -- | -- | 100% 0 to 140.0K | |
| 03-Jan-23 12:41 PM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 30-Dec-22 | Purchase | 29,000 | $1.55 | $44,834.00 | 1% 2.07M to 2.1M | |
| 03-Jan-23 12:41 PM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 29-Dec-22 | Purchase | 7,000 | $1.54 | $10,752.00 | < 1% 2.07M to 2.07M | |
| 28-Dec-22 4:40 PM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 28-Dec-22 | Purchase | 3,293 | $1.50 | $4,923.04 | < 1% 2.06M to 2.07M | |
| 28-Dec-22 4:40 PM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 23-Dec-22 | Market Purchase | 15,707 | $1.44 | $22,665.20 | < 1% 2.05M to 2.06M | (9%) |
| 22-Dec-22 3:19 PM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 22-Dec-22 | Purchase | 41,414 | $1.48 | $61,127.10 | 2% 2.0M to 2.05M | |
| 22-Dec-22 3:22 PM View: | Pratt Raymond Dennis Chief Medical Officer | Adventrx Pharmaceuticals Inc. (SVRA) | 22-Dec-22 | Purchase | 3,500 | $1.54 | $5,401.90 | 2% 150.0K to 153.5K | |
| 20-Dec-22 1:29 PM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 20-Dec-22 | Purchase | 13,830 | $1.50 | $20,758.80 | < 1% 1.99M to 2.0M | |
| 22-Dec-22 3:19 PM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 20-Dec-22 | Purchase | 3,586 | $1.48 | $5,307.28 | < 1% 2.0M to 2.0M | |
| 20-Dec-22 1:29 PM View: | Ramsay David A Director | Adventrx Pharmaceuticals Inc. (SVRA) | 19-Dec-22 | Purchase | 40,719 | $1.49 | $60,834.20 | 2% 1.95M to 1.99M |
